Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Universal Health Coverage Day 2018

 
Universal Health Coverage Day 2018
Unite for Universal Health Coverage: Now is the Time for Collective Action

http://www.emro.who.int/media/news/universal-health-coverage-day-2018.html

12 December 2018, Cairo ‒ Universal Health Coverage (UHC) Day, commemorated each 12 December, is the anniversary of the first unanimous United Nations resolution calling for countries to provide affordable, quality health care to every person, everywhere.

“UHC is a simple idea: that everyone should be able to access the health services they need, without suffering financial hardship. Globally, we have a lot of work to do to realise that dream,” said Dr Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization (WHO).

“At least half of the world's population cannot access essential services like vaccination, essential medicines, or the ability to see a health worker. And every year, nearly 100 million people are pushed into extreme poverty due to out-of-pocket health spending.”

In the WHO Eastern Mediterranean Region, around 40% of health expenditure comes directly from people’s pockets, and most people cannot afford it. People with low incomes and without social protection are the hardest hit. As a result, an estimated 7.5 million people are pushed into poverty every year in the Region due to spending on health.

UHC has a special relevance to people living in countries with acute and prolonged emergency situations, and therefore for the Region, given that half of the world’s internally displaced populations are living in countries of the Region and more than 60% of the world’s refugees and migrants originate from the Region.

Vision 2023, developed by Dr Ahmed Al-Mandhari, WHO Regional Director for the Eastern Mediterranean, to guide the Organization’s work, acknowledges the socioeconomic diversity, opportunities and challenges facing the Region and calls for solidarity and action to promote “Health for All by All”. In line with WHO’s Thirteenth General Programme of Work 2019–2023, Vision 2023 has identified expanding UHC as a top strategic priority for the Region, and focuses on implementing the recommendations of the Salalah Declaration on UHC of September 2018 to ensure that at least 100 million more people benefit from UHC by 2023.

“Vision 2023 is a renewed call to aspire to the goal of Health for All, but it also stresses that Health for All can only be achieved by All. To move towards UHC, we need to engage everyone – governments, parliaments, academic and professional institutions, nongovernmental organizations, our sister United Nations agencies, communities, civil society and individuals – as proactive agents for change,” said Dr Al-Mandhari.

“I am glad that the theme for UHC Day 2018 is in harmony with our vision of Health for All by All. We shall all unite for UHC. Now is the time for collective action.”

Ministers of health and heads of delegations from the countries of the Region have recently collectively signed the UHC2030 Global Compact, making the Region the first among WHO’s six regions to do so. The signing of the UHC2030 Global Compact demonstrates a high level of commitment to take action and make progress towards UHC by the countries of the Region. Furthermore, WHO’s Regional Committee for the Eastern Mediterranean in its 65th Session this year endorsed a resolution urging Member States to formulate a national vision for UHC and a roadmap towards its realization, taking into account country-specific health system challenges, the economic situation and people’s preferences.

The essence of UHC is the provision of an essential package of health services to the whole population and ensuring that those who cannot pay for health care are financially protected through prepayment schemes. Every country can make progress towards UHC, even low-income countries and those affected by emergencies. 

“Providing a basic package of health services for all, and then employing progressive universalism by building on this package as more resources become available, is the way to go about it”, said Dr Zafar Mirza, Director, Health System Development at the WHO Regional Office for the Eastern Mediterranean.
    ...
    136
    ...
ATC Name B/G Ingredients Dosage Form Price
L01CE02 IRNOCAM 40 G Irinotecan HCl - 40mg/2ml 40mg/2ml Injectable solution 908,694 L.L
J01GB03 GENTAMICINE PANPHARMA G Gentamicin (sulfate) - 40mg/2ml 40mg/2ml Injectable solution 643,701 L.L
L01FF01 OPDIVO BioTech Nivolumab - 40mg/4ml 40mg/4ml Injectable solution 51,234,726 L.L
L01FF01 OPDIVO BioTech Nivolumab - 40mg/4ml 40mg/4ml Injectable solution L.L
S01LA05 EYLEA BioTech Aflibercept - 40mg/ml 40mg/ml Injectable solution 65,161,855 L.L
H02AB04 DEPO MEDROL B Methylprednisolone acetate - 40mg/ml 40mg/ml Injectable suspension 182,763 L.L
H02AB08 TRIACORT G Triamcinolone acetonide - 40mg/ml 40mg/ml Injectable suspension 745,833 L.L
A03AX13 OVOL B Simethicone - 40mg/ml 40mg/ml Drops 233,829 L.L
L03AX03 SII-ONCO-BCG G Bacillus Calmette- Guerin Strain - 40mg/ml (1-8x10?CFU) 40mg/ml Injectable dry powder 6,987,981 L.L
L01FD01 KANJINTI BioTech Trastuzumab - 420mg 420mg Injectable powder for concentrate for solution 79,305,881 L.L
L01EL01 IMBRUVICA B Ibrutinib - 420mg 420mg Tablet, film coated L.L
L01EL01 IMBRUVICA B Ibrutinib - 420mg 420mg Tablet, film coated 562,026,556 L.L
L01FD02 PERJETA 420MG BioTech Pertuzumab - 420mg/14ml 420mg/14ml Injectable concentrate for solution 220,054,714 L.L
L01FD02 PERJETA 420MG BioTech Pertuzumab - 420mg/14ml 420mg/14ml Injectable concentrate for solution L.L
L01FD01 ARYOTRUST BioTech Trastuzumab - 440mg 440mg Injectable powder for concentrate for solution + solvent 34,948,930 L.L
L01FD01 HERZUMA BioTech Trastuzumab - 440mg 440mg Injectable powder for concentrate for solution 89,046,707 L.L
L01FD01 MABTIN 440 BioTech Trastuzumab (r-DNA origin) - 440mg 440mg Injectable powder for solution 70,042,700 L.L
L01FD01 OGIVRI BioTech Trastuzumab - 440mg 440mg Injectable lyophilised powder 80,027,615 L.L
L01FD01 TRASTUREL BioTech Trastuzumab - 440mg 440mg Injectable lyophilised powder 52,047,114 L.L
L01FD01 TRAZIMERA BioTech Trastuzumab - 440mg 440mg Injectable powder for solution+solvent 75,295,202 L.L
L03AB07 BLASTOFERON BioTech Interferon beta-1a - 44mcg 44mcg Injectable solution 55,847,685 L.L
L03AB07 RECIGEN 44 BioTech Interferon beta-1a - 44mcg/0.5ml 44mcg/0.5ml Injectable solution L.L
L03AB07 RECIGEN 44 BioTech Interferon beta-1a - 44mcg/0.5ml 44mcg/0.5ml Injectable solution 15,147,973 L.L
G03GA05 CINNAL-f BioHuman Follitropin alfa - 450IU/0.75ml 450IU/0.75ml Injectable solution 7,372,177 L.L
G03GA05 GONAL-f BioHuman Follitropin alfa - 450IU/0.75ml 450IU/0.75ml Injectable solution 14,813,959 L.L
J01MA23 BAXDELA B Delafloxacin - 450mg 450mg Tablet 93,777,847 L.L
J05AB14 VALCYTE B Valganciclovir (HCl) - 450mg 450mg Tablet, film coated 63,612,039 L.L
J05AB14 VAGLONAX G Valganciclovir (HCl) - 450mg 450mg Tablet, film coated 49,858,549 L.L
J05AB14 VALGANCICLOVIR ARROW G Valganciclovir (HCl) - 450mg 450mg Tablet, coated 44,309,215 L.L
J01CR02 AMOCLAN BID G Amoxicillin (trihydrate) - 400mg/5ml, Clavulanic Acid (potassium) - 57.1mg/5ml 457mg/57mg Tablet, chewable 892,311 L.L
    ...
    136
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025